Kexing (SINOVAC) COVID-19 vaccine will be produced in Egypt from June

News

Kexing (SINOVAC) COVID-19 vaccine will be produced in Egypt from June

Kexing (SINOVAC) COVID-19 vaccine will be produced in Egypt from June. China and Egypt signed a cooperation agreement for the localized production of the COVID-19 vaccine in Egypt.

[Global Times Special Correspondent in Egypt Huang Peizhao Global Times Correspondent Hao Shuangyan] According to reports from major Egyptian media such as the Pyramid, Egypt will realize the localization of vaccine production with the help of China. It is expected to cooperate with Beijing Kexing Company in Egypt. The first batch of vaccines produced will be available in mid to late June. The Minister of Health and Population of Egypt, Hala Zayed, inspected Egypt’s local vaccine manufacturers on the 9th and held a press conference to introduce to the media reporters Egypt’s current preparations for the localized production of China’s Kexing vaccine.

Zayed said at the press conference that according to the cooperation agreement for the localized production of China’s COVID-19 vaccine in Egypt signed between Kexing and Egyptian companies in April this year, 40 million doses of Kexing vaccine will be produced in the first year. On the 18th of this month, the raw materials used to produce Kexing vaccine will arrive in Cairo, and the first batch of 2 million doses of the COVID-19 vaccine will be produced by the end of June. After passing the strict review of the Egyptian Medicines Agency, these vaccines are expected to be officially launched in July. Zayed expressed his gratitude to China for helping Egypt realize the localized production of vaccines and its long-term assistance to Egypt.

Zayed said at the press conference that the vaccine produced in Egypt will first be used to ensure local demand, and the remainder will be exported to other countries in Africa. She emphasized that Egypt has a complete industrial chain and can transfer vaccine production technology to make Egypt a vaccine supply center in Africa. The Egyptian newspaper “Republic” stated that the joint production of vaccines between Egypt and China highlights Egypt’s trust in China and reflects that the Egyptian people feel at ease with China’s vaccines. In fact, China’s support and technology have enabled the localization of Egyptian vaccine production, which will have a huge effect on controlling and defeating the COVID-19 epidemic.

In addition to Egypt, other countries in the Middle East are also very interested in Chinese vaccines, especially the United Arab Emirates, which plans to build a “Middle East vaccine hub” that radiates West Asia and North Africa with the help of China. As early as November last year, the Vice President and Prime Minister of the United Arab Emirates, Dubai Chief Al Maktoum and other senior officials were vaccinated with the COVID-19 vaccine developed by Sinopharm Group. In January of this year, the UAE Ministry of Health and Prevention announced that the UAE government’s cooperative scientific research institutes and China National Pharmaceutical Group have reached an agreement to produce Sinopharm vaccines locally under the authorization of China. According to the UAE’s Gulf News, the vaccine produced by Sinopharm Group and UAE G42 Group is called “Hayat-Vax” (Arabic for “seedlings of life” or “seeds of hope”), which will greatly speed up the country Vaccination progress of 205 medical centers.

In addition, in Brazil, the Butantan Institute, a partner of Beijing Kexing Company, has imported stock solutions from China to produce vaccines locally, and has delivered more than 45 million doses of COVID-19 vaccine to the vaccination plan of the Brazilian Federal Government. The Butantan Institute expects that starting from December this year, the agency will produce 100% of the Coxing vaccine in Brazil.

A person in the Chinese industry who understands the situation told the Global Times reporter on the 10th that the epidemic

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.